alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1,401–1,425 of 3,821 studies published 2025 (page 57 of 153) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Identifying dementia risk profiles for targeted interventions: A latent class analysis of at‐risk middle‐aged Australians

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Alzheimer s & Dementia 2025-11-01

Among 403 participants (mean age 56.4 ± 5.7 years, 62.5% female), the median number of dementia risk factors was 5.0; hyperlipidaemia (92.5%), low cognitive activity (72.5%), obesity (57.6%), and hypertension (52.7%) were the most prevalent. 5 key findings →

Design: cross-sectional Participants: 403 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Delirium prevalence, diagnostic uncertainty and outcomes in ORCHARD-EPR: validation against prospective reference cohorts

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Age and Ageing 2025-08-29

Among 18 614 ORCHARD-EPR patients (mean/SD age = 82.9/7.4 years, dementia = 20%), certain delirium (delirium = yes or ICD-10 delirium code) was present in 3077/18 614 (17%,95%CI 16%-17%) of whom 1199/3077 (39%) had dementia, and uncertain delirium (delirium = uncertain and no ICD-10 code) in 2007 (11%,10%-11%) of whom 773/2007 (39%) had dementia. 5 key findings →

Participants: 731 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

“By the Time We Knew …”: Poetic Analysis of End‐of‐Life Caregiving Experiences for Rapidly Progressive and Slower‐Duration Dementia Syndromes

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of the American Geriatrics Society 2025-02-05

"Rapid-type" caregivers (n = 12) had a median age of 59 (range 45-73) years; 6 were female, and 9 were spouses. 5 key findings →

Participants: 12 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Sharing patient technology preferences with care networks: Stakeholders’ views of the “Let’s Talk Tech” decision aid for dementia care

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of Alzheimer s Disease 2025-05-01

BackgroundLet's Talk Tech (LTT) is a self-administered web intervention for people with memory loss and their care partners that supports decision-making about digital health technologies. 5 key findings →

Participants: 15 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Antihypertensive Deprescribing and Functional Status in VA Long‐Term Care Residents With and Without Dementia

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of the American Geriatrics Society 2025-01-03

In long-term care residents, ADL scores worsened by a mean of 0.29 points (95%CI = 0.27, 0.31) per 3 months and antihypertensive deprescribing did not impact this worsening (difference between groups -0.04 points every 3 months, 95%CI = -0.15, 0.06). 5 key findings →

Participants: 12,238 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cerebral small vessel disease: The impact of glymphopathy and sleep disorders

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of Cerebral Blood Flow & Metabolism 2025-05-05

The glymphatic system, a vital brain perivascular network for waste clearance, hinges on the functionality of the aquaporin 4 (AQP4) water channel. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Neurovascular Decoupling Is Associated With Lobar Intracerebral Hemorrhages and White Matter Hyperintensities

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of the American Heart Association 2025-02-14

This raises the suggestion that a decreased neurovascular coupling in the disease process of AD is related to comorbid small vessel disease. 2 key findings →

Participants: 119 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Higher Burden of Cerebral Small Vessel Disease Is Associated With Risk of Incident Stroke in Community‐Dwelling Individuals

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of the American Heart Association 2025-11-06

Among 1154 participants (46% men, mean age 70.9±8.7 years), 92 (8%) developed stroke over a median follow-up of 8.6 years (Q1-Q3: 5.1-12.5). 5 key findings →

Participants: 1,154 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Associations of early-onset coronary heart disease and genetic susceptibility with incident dementia and white matter hyperintensity: A prospective cohort study

✓ Peer-reviewed alzhub usefulness score 47 out of 100. The Journal of Prevention of Alzheimer s Disease 2025-01-23

=0.002). Early-onset CHD and genetic susceptibility are associated with a higher risk of incident dementia and a larger WMH volume. 2 key findings →

Design: cohort study Participants: 671 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

DCE-MRI reveals spatial pattern in heterogeneous blood-brain barrier leakage within white matter in cerebral small vessel disease

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of Cerebral Blood Flow & Metabolism 2025-08-04

Cerebral small vessel disease (cSVD) is associated with vascular cognitive impairment, dementia, and stroke. 3 key findings →

Design: cross-sectional Participants: 59 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Unraveling Homocysteine's Role in Dementia: No Specific Association with Alzheimer's Disease, but a Connection to White Matter Hyperintensities

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Aging and Disease 2025-01-01

Hyperhomocysteinemia (HHcy) is an established risk factor for cognitive impairment. 2 key findings →

Design: cross-sectional Participants: 507 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cerebral small vessel disease and effects of intensive versus standard blood pressure treatment on cardiovascular outcomes and adverse events

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of Hypertension 2025-06-27

The mean age of the participants was 68 ± 9 years and 39% were female. 5 key findings →

Design: post-hoc analysis Participants: 759 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Human induced pluripotent stem cell models for Alzheimer's disease research: a bibliometric analysis

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Frontiers in human neuroscience 2025-03-19

Bibliometric analysis is crucial in identifying research gaps and trends and guiding future studies to address unmet needs in understanding and modeling human physiology and pathology. 1 key finding →

Design: systematic review Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

New landscape of the diagnosis of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Lancet (London, England) 2025-09-22

Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individuals, and a leading source of health and social care expenditure for society. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Science (New York, N.Y.) 2025-08-07

Amyloid-related imaging abnormalities (ARIA), side effects of anti-amyloid drugs seen in magnetic resonance imaging of the brain, are a major safety concern in patients with Alzheimer's disease. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Changes in Out-of-Pocket Drug Expenditures Among Medicare Beneficiaries With Dementia Under the Inflation Reduction Act: A Simulation Study

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Value in Health 2025-01-27

The Inflation Reduction Act Medicare Part D benefit redesign will reduce OOP drug spending for beneficiaries with dementia, resulting in potentially marked savings not only for low-income beneficiaries and beneficiaries with a high comorbidity burden but also for higher-income beneficiaries. 1 key finding →

Design: modelling Participants: 1,677 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Mixed Pathologies and Cognitive Outcomes in Persons Considered for Anti-Amyloid Treatment Eligibility Assessment: A Community-Based Study

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Neurology 2025-08-18

Among 428 older autopsied persons (mean age at death = 91 years, 70% women) considered for anti-amyloid treatment eligibility assessment, 58% had MCI and 42% had mild-stage Alzheimer dementia. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed